Who are Irazu Oncology's investors?

Irazu Oncology's investors include Maryland TEDCO, TEDCO.

How much funding has Irazu Oncology raised?

Irazu Oncology has disclosed $2.6M raised across 1 round.

Where is Irazu Oncology headquartered?

Irazu Oncology is headquartered in Baltimore, US.

Irazu Oncology

Baltimore, US · Founded 2022 · Delaware LLC · 2 known investors

Find your way into Irazu Oncology

Paths you didn't know you had: your email and LinkedIn already hold routes to the Irazu Oncology team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Irazú Oncology develops cancer immunotherapies using a proprietary Outer Membrane Vesicles (OMV) platform based on engineered bacterial nanoparticles that deliver cancer antigens. The biotech company, founded in 2022, is building a pipeline of immunotherapies for cancer patients.

Biotech Healthtech Medical Devices

Founders & leadership

Jeff Strovel Chief Executive OfficerJeff Strovel holds a PhD and has led drug discovery and development programs across multiple therapeutic areas including cancer biology and epigenetics. He co-founded VERALOX Therapeutics, helped establish Noble Life Sciences, and held leadership roles at Avalon Pharmaceuticals where he directed strategic partnerships with entities including Sanofi Genzyme and the NIH.

James BerensNamed on SEC filing

Richard KohrNamed on SEC filing

Investors · 2

Maryland TEDCOlisted by Maryland TEDCOColumbia · $500K – $1.5M

How we know: Maryland TEDCO's portfolio page · Not right? Tell us

TEDCOlisted by TEDCOColumbia

Reported raises · per SEC filings

Form D private placements

$2.6M disclosed across 1 round · 2023

▶$2.6MraisedDec 2023 · 6 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

James BerensExecutive Officer
Richard KohrExecutive Officer

Offering amount: $3.9M
Amount sold: $2.6M
First sale: Nov 2023
Incorporated: Limited Liability Company, Delaware, 2022
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Irazu Oncology do?: Irazú Oncology develops cancer immunotherapies using a proprietary Outer Membrane Vesicles (OMV) platform based on engineered bacterial nanoparticles that deliver cancer antigens. The biotech company, founded in 2022, is building a pipeline of immunotherapies for cancer patients.
Who are Irazu Oncology's investors?: Irazu Oncology's investors include Maryland TEDCO, TEDCO.
How much funding has Irazu Oncology raised?: Irazu Oncology has disclosed $2.6M raised across 1 round.
Where is Irazu Oncology headquartered?: Irazu Oncology is headquartered in Baltimore, US.